Inhibition of telomerase using BIBR1532 followed by ALT (alternative lengthening of telomere) inhibition by trabectedin—the ALT pathway is activated in advanced cHL [126]—caused a decrease of greater than 90% in cell viability in three patient-derived HL cell lines [127]. This evidence concerns the gene GPT and Hodgkins lymphoma.